An interventional study of cryoSPHERE Ablation and Bupivacaine in Pain and Pain, Postoperative, sponsored by The Methodist Hospital Research Institute. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2023-03-24.
Sponsored by The Methodist Hospital Research Institute · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,181 studies in Pain, Postoperative with a site in United States — 204 open to participants now, 237 under way, 25 of them phase 3. Pain, Postoperative · United States.
Among the 1,181 studies in Pain, Postoperative with a site in United States, this one is the 556th largest by planned enrollment of the 1,099 interventional ones that give a count, is one of 55 that started in 2023, is one of 373 with no phase, reaches primary completion later than 18 of the 236 other live ones, and was the 894th registered.
5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.
Browse Pain, Postoperative studies →204 of the 1,181 studies in Pain, Postoperative with a site in United States are open now. Recruiting first, the newest first:
Loma Linda University · Sites in United States
Ages 18+ · Men only
Columbia University · Sites in United States
Ages 12–21
Duke University · Sites in United States
Ages 18+ · Healthy volunteers
Stanford University · Sites in United States
Ages 18+ · Women only
Hospital for Special Surgery, New York · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,181 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 66 · Phase 2 156 · Phase 3 179 · Phase 4 359
First in 1996; this study’s year is marked. 55 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 75 is close to the median of 75 across 4,859 interventional studies indexed under Pain, Postoperative.
Median enrollment 76 across the 1,099 interventional studies, 130 across the 82 observational. Of the 784 that completed or were terminated, 475 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
200 of 1,181 have an industry lead sponsor. The 10 most frequent:
The Methodist Hospital Research Institute is the lead sponsor of 162 studies on the registry; 61 are open to participants now.
Of its 28 completed or terminated interventional studies of FDA-regulated products, 18 (64%) have results posted.
The Methodist Hospital Research Institute has 3 studies filed under Pain, Postoperative — fewer than ten, so there is no comparison to draw.
98 of the studies in Pain, Postoperative with a site in United States that are under way reach primary completion within a year, 13 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07060495Phase 3Rutgers, The State University of New JerseyRADA16 for Adult Tonsillectomy | 2026-12-01 |
| NCT07539623Phase 3Icahn School of Medicine at Mount SinaiSuzetrigine-enhanced MultimOdal Opioid-sparing THerapy in Cardiac and Bariatric SURGery | 2026-12-22 |
| NCT07226076Phase 3Medical University of South CarolinaMethadone in TKA for Post-op Pain and Opioid Reduction | 2026-12-28 |
| NCT07565870Phase 3Alexandre P. JoostenMethadone for Enhanced Postoperative Analgesia in Intermediate-Risk Noncardiac Surgery (MELODY) | 2026-12-31 |
| NCT05058287Phase 3Hospital for Special Surgery, New YorkLumbar Steroid Use in Patients Undergoing Posterior Lumbar Decompression | 2026-12-31 |
Add all 98 to your calendar (.ics) → With an account.
Among the 1,181 studies in Pain, Postoperative with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main objective study is to compare the use of the cryoSPHERE probe to the standard-of-care method for pain management of patients receiving robotic-assisted thoracoscopic surgery, including reductions in opioid pain medication use and the development of post-surgical morbidity.
Patients who take more opioid medications after surgery tend to have longer hospital stays, and they are at risk of developing pneumonia and other postoperative morbidities. Opioid-tolerant patients are at a higher risk of developing these morbidities because they often require higher doses of opioid medications to manage their post-operative pain. Reducing post-operative pain in these patients through non-opioid means helps reduce their risk of developing morbidities, and is potentially a more effective form of pain management, particularly in this patient population.
This is a single-center, prospective cohort registry with a historical control, and an estimated duration of 2 years. This study's primary objective is to evaluate the cryoSPHERE probe for ablation in pain control after surgery (measured using opioid medication). The secondary objectives are the evaluation of morbidities, length of stay, cost, and incidence of neuroma formation.
We plan to recruit 75 patients who will receive the cryoSPHERE probe and compare them to 75 patients who did not receive the cryoSPHERE probe. The experimental group will receive cryoSPHERE ablation of intercostal nerves and liposomal bupivacaine. The historical control group will have had robotic-assisted thoracoscopic surgery and an intercostal nerve block with liposomal bupivacaine and no cyroSPHERE probe.
5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.
This study's planned enrollment of 75 is close to the median of 75 across 4,859 interventional studies indexed under Pain, Postoperative.
Browse Pain, Postoperative studies →The Methodist Hospital Research Institute is the lead sponsor of 162 studies on the registry; 61 are open to participants now.
Of its 28 completed or terminated interventional studies of FDA-regulated products, 18 (64%) have results posted.
Compared within Pain, Postoperative, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Pain. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The experimental group (75 participants) will undergo intercostal nerve block using liposomal bupivacaine and the cryoSPHERE ablation of intercostal nerves during robotic-assisted thoracoscopic operation at Houston Methodist Hospital.
Device: cryoSPHERE Ablation · Drug: Bupivacaine
A total of 75 propensity score-matched historical controls will be selected from the pool of patients who had standard intercostal nerve block using liposomal bupivacaine alone at Houston Methodist Hospital from January 1, 2017 through January 1, 2022, inclusively.
Drug: Bupivacaine
The cryoSPHERE probe will be introduced through a thoracoscopic port and placed inferior to each rib level and 2cm lateral and away from the sympathetic chain when clearly visible or 4cm lateral and away from the spine when the sympathetic chain is not visible. Levels to be ablated are intercostal spaces 3-9. Each intercostal nerve will undergo cryogenic ablation of -70 degrees Celsius for 120 seconds. The probe will be firmly pushed against the nerve for 120 seconds and will only be released from the nerve when the probe has thawed. Axons within the intercostal nerve that send pain signals will be destroyed distal to the cryoablation site. However, the tubules structures (epineurium, perineurium, and endoneurium) of the nerve will remain intact, allowing the axons to regenerate and nerve function to resume after one to three months.
Also known as: cryoSPHERE
A long needle will be introduced through a thoracoscopic port, and in each intercostal space (1-11), 1ml of liposomal bupivacaine will be injected onto the intercostal nerves to induce intercostal nerve blockage.
Also known as: liposomal bupivacaine, Exparel
Opioid Use Within 24 Hours After Chest Tube Removal
Opioid use measured as the daily dose of milligram morphine equivalents (MME)
Time frame: From the time of chest tube removal to 24 hours after chest tube removal
Total Emergent Adverse Effects (TEAE)
Morbidity, defined as total emergent adverse effects (TEAE) for the experimental group vs. control
Time frame: Time of discharge (up to 1 year after surgery), 5 weeks after surgery, 3 months after surgery, and 6 months after surgery
Length of Hospital Stay
Time spent in the hospital from admission for surgery until discharge or death
Time frame: From admission to discharge or death, up to 1 year after surgery
Mean Cost of Hospital Care
Total cost of billed medical care for the surgery
Time frame: From admission to discharge or death, up to 1 year after surgery
Number of Readmissions
The number of readmissions to the hospital
Time frame: From initial admission for surgery to 28 days after surgery
Neuroma Formation
The formation of a neuroma around the site of nerve block administration
Time frame: Time of discharge (up to 1 year after surgery), 3 months after surgery, and 6 months after surgery
Pain Score
Patient's perceived pain level on a scale of 1 to 10
Time frame: Time of discharge (up to 1 year after surgery), 5 weeks after surgery, 3 months after surgery, and 6 months after surgery
PROMIS3a Pain Intensity
Patient's perceived pain level on a scale of 3-15, per PROMIS Pain Intensity Short Form 3a v1.0
Time frame: Time of discharge (up to 1 year after surgery), 5 weeks after surgery, 3 months after surgery, and 6 months after surgery
PROMIS8a Pain Interference
Patient's perceived pain interference level on a scale of 8-40, per PROMIS Pain Interference Adult Form
Time frame: Time of discharge (up to 1 year after surgery), 5 weeks after surgery, 3 months after surgery, and 6 months after surgery
Opioid Use after Surgery
Mean daily opioid use after surgery measured in milligram morphine equivalents (MME)
Time frame: Day 1 after surgery, day 3 after surgery, 5 weeks after surgery, 3 months after surgery
Plan to share: No
Started Feb 2023 (actual). Primary completion is estimated for Mar 2025, 25 months after the start.
Of 2,113 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 25 months is above that.
Counting every sponsor, half of 2,126 studies reached it within 11 months; a quarter within 6 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The Methodist Hospital Research Institute →